CCC launches regulatory compliance portal

Share this article:

Responding to the billions of dollars in industry fines paid under the False Claims Act, The Center for Communication Compliance (CCC) has launched a new online compliance portal. 

Chaired by former FDA employee Wayne Pines, the CCC portal offers regulatory compliance tests (RCTs) online. Current RCTs available on the website range from $100 for an “advanced test,” and $300 for a “basic test.” Public relations RCTs are available now, with advertising and promotional medical education RCTs launching in September, according to CCC president and founder Ilyssa Levins. Participants scoring higher than 80% on the test will receive a certificate of “regulatory compliance competency.”

Public relations agencies Weber Shandwick and Porter Novelli have both committed to certifying their healthcare staff in all US offices, according to a company statement. In addition to the RCT certification, healthcare professionals can purchase consulting packages for reviewing campaign materials, from the initial campaign conception, to programing and actual ads, notes Levins.

Advisory board members at CCC include Jill Alvarez, JD, partner, Nixon Peabody Technology and Intellectual Property Group, Alan Bennett, JD, managing partner at Ropes & Gray, Glenn Byrd, MBA, RAC, director of regulatory affairs at MedImmune, and Dr. John Kamp, executive director of the Coalition for Healthcare Communication, among others.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...